



European Patent Office approves instagraft patent

S2Medical AB (publ) has today received the response from the European Patent Office that they intend to grant patent protection for the Company's instagraft technology within around forty European countries.

The instagraft technology is a surgical instrument that can be used for minimally invasive skin transplantation and is intended to move this procedure from specialist units out to the primary healthcare units. This would result in a higher number of patients suffering from chronic ulcers getting access to skin transplantation and thereby being able to heal their wounds.

"The instagraft technology has reached patent protection in several countries around the world. We see Europe as a big potential market for the technology and are therefore very happy that we have received a substantial widening of the patent protection in this region." Says the Company's CEO Petter Sivlér.

This disclosure contains information that S2Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-08-2022 16:11 CET.

Contact Details

Petter Sivlér – CEO, S2Medical AB (publ)

Telephone: +46 (0)8-70 000 50

E-mail: petter.sivler@s2m.se

Certified Adviser

Vator Securities AB

Telephone +46 (0)8-580 065 99

Website: www.vatorsec.se

E-mail: ca@vatorsec.se

About S2Medical

S2Medical AB (publ) is a medical technology company that develops and sells innovative wound healing products for the entire wound healing process, with a focus on burns and chronic wounds. The company has developed eiratex®, a new cellulose-based material for healing severe burns and chronic wounds. The material heals wounds effectively and thereby reduces both suffering for patients and costs for health care.

Share's ticker: S2M

Share's ISIN-code: SE0011725084